Table 1.

Patient characteristics at baseline

All (n = 202)ABI arm (n = 101)ENZ arm (n = 101)P value
Age75.3 (49.3–94.1)72.9 (51.3–93.3)77.6 (49.3–94.1)0.025
PSA (ng/mL)36.1 (1.7–2817)35.0 (2.2–2817)37.0 (1.7–1060)0.286
ALP (ULN)0.81 (0.29–47.8)0.82 (0.29–12.5)0.75 (0.30–47.8)0.771
LDH (ULN)0.79 (0.31–12.9)0.79 (0.37–4.0)0.80 (0.31–12.9)0.332
Hemoglobin (g/L)130 (89–165)130 (89–155)130 (89–165)0.988
ECOG PS 0–1168 (83.2%)89 (88.1%)79 (78.2%)0.090
Bone metastases169 (83.7%)86 (85.1%)83 (82.2%)0.704
Lung metastases15 (7.4%)7 (6.9%)8 (7.9%)1.000
Liver metastases12 (5.9%)5 (5.0%)7 (6.9%)0.767
cfDNA (ng/mL plasma)13.0 (1.5–3871)12.4 (1.5–258)13.3 (1.5–3871)0.424
ctDNA >2%115 (56.9%)56 (55.4%)59 (58.4%)0.839
  • NOTE: Alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) levels are reported relative to upper limit of normal (ULN).

  • Abbreviations: ABI, abiraterone; ECOG PS, Eastern Cooperative Oncology Group performance status; ENZ, enzalutamide; PSA, prostate-specific antigen.